EP0449998A4 - Antibody-oxidase conjugates with non-systemic substrates - Google Patents

Antibody-oxidase conjugates with non-systemic substrates

Info

Publication number
EP0449998A4
EP0449998A4 EP19900908348 EP90908348A EP0449998A4 EP 0449998 A4 EP0449998 A4 EP 0449998A4 EP 19900908348 EP19900908348 EP 19900908348 EP 90908348 A EP90908348 A EP 90908348A EP 0449998 A4 EP0449998 A4 EP 0449998A4
Authority
EP
European Patent Office
Prior art keywords
systemic
antibody
substrates
oxidase
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900908348
Other languages
English (en)
Other versions
EP0449998A1 (fr
Inventor
John D. Duncan
Frieder K. Hofmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brunswick Corp
Original Assignee
Brunswick Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brunswick Corp filed Critical Brunswick Corp
Publication of EP0449998A1 publication Critical patent/EP0449998A1/fr
Publication of EP0449998A4 publication Critical patent/EP0449998A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP19900908348 1989-06-30 1990-03-21 Antibody-oxidase conjugates with non-systemic substrates Withdrawn EP0449998A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37404889A 1989-06-30 1989-06-30
US374048 1989-06-30

Publications (2)

Publication Number Publication Date
EP0449998A1 EP0449998A1 (fr) 1991-10-09
EP0449998A4 true EP0449998A4 (en) 1992-01-15

Family

ID=23475040

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900908348 Withdrawn EP0449998A4 (en) 1989-06-30 1990-03-21 Antibody-oxidase conjugates with non-systemic substrates

Country Status (3)

Country Link
EP (1) EP0449998A4 (fr)
AU (1) AU5732290A (fr)
WO (1) WO1991000108A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
TR200101638T2 (tr) * 1998-12-11 2001-10-22 Unilever N.V. Ağartıcı enzimler ve bu enzimleri içeren deterjan bileşimleri

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001720A1 (fr) * 1984-09-13 1986-03-27 Cytogen Corporation Conjugues d'agents therapeutiques-anticorps
EP0361908A2 (fr) * 1988-09-28 1990-04-04 Ideon Corporation Immunothérapie à base d'une combinaison d'enzymes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496539A (en) * 1982-02-01 1985-01-29 Massachusetts Institute Of Technology Method for treating cancer using galactose-specific lectins
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001720A1 (fr) * 1984-09-13 1986-03-27 Cytogen Corporation Conjugues d'agents therapeutiques-anticorps
EP0361908A2 (fr) * 1988-09-28 1990-04-04 Ideon Corporation Immunothérapie à base d'une combinaison d'enzymes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9100108A1 *

Also Published As

Publication number Publication date
EP0449998A1 (fr) 1991-10-09
AU5732290A (en) 1991-01-17
WO1991000108A1 (fr) 1991-01-10

Similar Documents

Publication Publication Date Title
ZA904162B (en) Glass composition
AU6061390A (en) Can carrier
ZA901086B (en) Conjugates
GB8905511D0 (en) Preparing substrates
AU5747190A (en) Air-flow meter
AU5606790A (en) Shaped articles
GB2228488B (en) Coextrudable adhesives
AU6516990A (en) Securing device
EP0434269A3 (en) Sandwich glass
GB8918590D0 (en) Turntables
AU5546090A (en) Antibody-lactate oxidase conjugates
HK41594A (en) Improved clip
AU5732290A (en) Antibody-oxidase conjugates with non-systemic substrates
AU6877391A (en) Display devices
EP0430866A3 (en) Connection piece
AU637395B2 (en) Advertising device
AU5370690A (en) Palmball
GB8925781D0 (en) Glass retaining member
AU5987190A (en) Improved clip
GB8911325D0 (en) Substrates
BG48014A1 (en) Glass
GB8909178D0 (en) Glass sheet handler
GB8927062D0 (en) Improvements in polymeric substrates
YU102089A (en) Fast disasembling connection
GB2236004B (en) Display device.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910729

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI SE

A4 Supplementary search report drawn up and despatched

Effective date: 19911125

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE FR GB IT LI SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920211